EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences announces activation of Phase 3 trial in Poland
Greenwich LifeSciences (GLSI) announced the activation of clinical sites in Poland in tis Phase III clinical trial, FLAMINGO-01, which is ...
Nasdaq3d
Greenwich LifeSciences Expands FLAMINGO-01 Trial With Polish Collaboration
(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Monday announced the activation of multiple clinical sites in Poland for its Phase III clinical ...
Yahoo Finance3d
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Mena FN3d
Greenwich Lifesciences Announces Activation Of Flamingo-01 In Poland
(MENAFN- GlobeNewsWire - Nasdaq) STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage ...
news.stocktradersdaily4d
How to Take Advantage of moves in (GLSI)
Check the time stamp on this data. Updated AI-Generated Signals for Greenwich Lifesciences Inc. (GLSI) available here: GLSI.